Hosted on MSN2d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...
Zacks.com on MSN2d
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
Healio10d
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...
Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
Intellia Therapeutics to Lay Off 27% of Workers in Reorganization
Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to ...